Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC

3365

Studies in scope

all four open statuses

1831

Recruiting now

open to new participants

500

Lead sponsors

across recruiting studies

Top sites

Seoul 195 Goyang-si 72 Daegu 59 Seongnam-si 59 Busan 50

Narrow the registerReset

Search within results

Recruitment status

Lead sponsor

Clear sponsor filter

Site location

All 52 locations

Target enrolment

Trials with a site in Seoul

Status

Study

Lead sponsor

Phase

Enrol

Sites in South Korea

Start

Not yet open

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

600

Goyang-si, Seoul

2026-09-29

Recruiting

BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA

NCT07570394Chronic Obstructive Pulmonary Disease (COPD), Asthma

AstraZeneca

Observational

600

Chuncheon, Daegu, Goyang-si, Gwangmyeong, Jinju, Seongnam-si, Seoul, Wŏnju

2026-09-17

Recruiting

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

NCT07851025Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

950

Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan

2026-09-16

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugsBalcinrenone/dapagliflozin·Dapagliflozin

AstraZeneca

Phase 3

2,800

Anyang, Cheonan-si, Seoul, Wŏnju, Yangsan

2026-09-01

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Seoul

2026-08-31

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Seoul

2026-08-25

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongbuk-Gu, Seoul

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul

2026-08-21

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Busan, Daegu, Daejeon, Incheon, Seoul, Suwon

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Anyang, Bucheon-si, Daegu, Seoul, Yangsan

2026-08-19

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Seoul

2026-07-16

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553Type 2 Diabetes Mellitus

DrugElecoglipron

AstraZeneca

Phase 3

600

Bucheon-si, Gyeonggi-do, Jongno-gu, Junggu, Seoul

2026-07-08

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

2,000

Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Yangsan

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Jongno-gu, Seongnam-si, Seoul

2026-07-06

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon

2026-06-29

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Seoul

2026-06-26

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Cheonan-si, Daegu, Goyang-si, Hwasun-eup, Incheon, Seongbuk-Gu, Seongnam-si, Seoul

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Seongnam-si, Seoul

2026-06-11

Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934Metastatic Prostate Cancer

DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel

AstraZeneca

Phase 1/2

152

Seoul

2026-06-03

Recruiting

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

NCT07529717Metastatic Prostate Cancer

AstraZeneca

Phase 1/2

Seoul

2026-05-18

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Goyang-si, Seoul

2026-05-04

Recruiting

Danicopan PMS in Korea

NCT07457151Paroxysmal Nocturnal Hemoglobinuria

AstraZeneca

Observational

Busan, Hwasun-gun, Seoul

2026-04-10

Recruiting

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

NCT07391670Solid Tumours

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 1

Seongnam-si, Seoul

2026-03-31

Recruiting

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855Solid Tumours

DrugSaruparib

AstraZeneca

Phase 1/2

180

Seoul

2026-03-17

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Seoul

2026-02-23

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Daegu, Hwasun-gun, Seongnam-si, Seoul

2026-02-03

Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

DrugPosaconazole

AstraZeneca

Phase 1/2

Seoul

2026-01-09

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan

2025-12-29

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Busan, Daegu, Seongnam-si, Seoul

2025-12-04

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414Advanced Solid Tumors

DrugsRecombinant Human Hyaluronidase·Rilvegostomig

AstraZeneca

Phase 1

Seoul

2025-11-25

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Seongbuk-Gu, Seoul

2025-11-24

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Seoul

2025-11-12

Recruiting

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

NCT07215585Large B-cell Lymphoma

DrugsR-mini-CHOP·Surovatamig

AstraZeneca

Phase 3

420

Seoul

2025-11-11

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Anyang-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Ulsan

2025-11-06

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

Seoul

2025-11-03

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Goyang-si, Incheon, Seoul, Suwon

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

Bukgu, Goyang-si, Seoul

2025-10-30

Recruiting

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

NCT06927648Breast Cancer

AstraZeneca

Observational

130

Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon

2025-10-15

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Seoul

2025-10-01

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Seoul

2025-09-30

Recruiting

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07123454B-cell Non-Hodgkin Lymphoma

AstraZeneca

Phase 1/2

Seoul

2025-09-24

Recruiting

Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

NCT06995833Endometrial Cancer

AstraZeneca

Observational

Seoul

2025-09-19

Not yet open

LTFU for All Cell and Gene Therapy Studies

NCT06194461Hepatocellular Carcinoma, Prostate Cancer

DrugsAZD0754·AZD5851

AstraZeneca

Observational

Seoul

2025-09-17

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon

2025-08-07

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Busan, Daegu, Goyang-si, Seongnam-si, Seoul

2025-08-06

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Goyang-si, Gwangjin-gu, Seoul, Songpa-gu, Suwon

2025-08-01

Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

120

Seoul

2025-07-29

Active, closed

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

NCT07000149Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Volrustomig

AstraZeneca

Phase 1

Busan, Seoul

2025-07-28

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Anyang-si, Cheongju-si, Chuncheon, Daegu, Jeonju, Seongnam-si, Seoul, Wŏnju

2025-06-27

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136Heterozygous Familial Hypercholesterolaemia

DrugAZD0780

AstraZeneca

Phase 3

473

Gyeonggi-do, Seoul

2025-06-10

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul

2025-05-06

Recruiting

Imjudo & Imfinzi PMS

NCT06544629Hepatocellular Carcinoma

AstraZeneca

Observational

246

Busan, Goyang, Seongnam, Seoul, Suwon

2025-04-14

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Jinju, Seoul

2025-04-10

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Goyang-si, Seoul, Suwon

2025-03-27

Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022Hepatocellular Carcinoma

AstraZeneca

Phase 1/2

304

Seoul

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Cheongju-si, Daegu, Seoul

2025-03-26

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wŏnju

2025-03-18

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan

2025-03-14

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Seoul, Yongin-si

2025-03-12

Active, closed

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462Ophthalmic Safety in Patients With Breast Cancer

AstraZeneca

Observational

160

Seoul

2025-03-05

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Daegu, Goyang-si, Gyeonggi-do, Jeonnam, Seoul

2025-03-01

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Busan, Seoul

2025-01-30

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Gyeonggi-do, Seoul, Songpa-gu

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Seoul

2024-11-27

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon

2024-11-18

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon

2024-10-04

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

Seongnam, Seoul, Suwon

2024-08-27

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Incheon, Namdong-gu, Seoul

2024-08-22

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Busan, Gyeonggi-do, Hwasun-gun, Seongnam-si, Seoul

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Busan, Goyang-si, Jeonnam, Seoul

2024-08-07

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Daegu, Seongnam-si, Seoul

2024-08-01

Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Rituximab

AstraZeneca

Phase 2

Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon

2024-07-16

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Seoul

2024-06-29

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Daejeon, Seoul

2024-06-20

Recruiting

Real-World Treatment Study of Koselugo (Selumetinib)

NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform

AstraZeneca

Observational

200

Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju

2024-06-15

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

Goyang-si, Namdong-gu, Seoul, Suwon

2024-04-29

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Cheongju-si, Seongnam-si, Seoul, Suwon

2024-04-21

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Changwon, Incheon, Seongnam-si, Seoul, Suwon

2024-04-11

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul

2024-03-29

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Gyeonggi-do, Seoul

2024-03-04

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan

2024-02-21

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

Seoul

2024-01-23

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

Seoul

2024-01-18

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Seoul

2023-12-29

Active, closed

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06084884Hepatocellular Carcinoma

DrugAZD5851

AstraZeneca

Phase 1/2

Seoul

2023-12-14

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon

2023-12-14

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Gyeonggi-do, Seoul

2023-12-13

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Seoul

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Seongnam-si, Seoul

2023-12-04

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Busan, Daegu, Goyang-si, Seongnam-si, Seoul

2023-11-23

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Daejeon, Seongnam-si, Seoul, Suwon

2023-11-21

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Daegu, Goyang-si, Seongnam, Seoul

2023-11-14

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Seoul

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Busan, Seoul

2023-11-08

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Ansan-si, Busan, Cheonan-si, Daegu, Goyang-si, Seoul

2023-11-07

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Cheongju-si, Incheon, Jinju, Seoul, Suwon

2023-10-24

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Cheonan-si, Daegu, Goyang-si, Seongnam-si, Seoul

2023-10-05

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Daegu, Goyang-si, Gyeonggi-do, Seoul

2023-09-22

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Seongnam-si, Seoul

2023-08-24

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Seoul

2023-08-16

Active, closed

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

NCT05801029Non-Small Cell Lung Cancer (NSCLC)

DrugsAmivantamab·Osimertinib

AstraZeneca

Phase 2

Anyang-si, Busan, Daegu, Seoul

2023-07-18

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

392

Seoul

2023-07-11

Active, closed

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644Advanced Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

111

Gyeonggi-do, Seongnam-si, Seoul

2023-06-27

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Seoul

2023-06-05

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

NCT05629234Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

Cheongju-si, Goyang-si, Seongnam-si, Seoul, Tonggu

2023-05-08

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Seongnam-si, Seoul

2023-04-24

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Cheongju-si, Junggu, Seoul

2023-04-05

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Busan, Daegu, Donggu, Goyang-si, Jeonnam, Seongbuk-Gu, Seoul

2023-03-31

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul

2023-03-06

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Seoul

2023-01-16

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Busan, Cheongju-si, Jinju, Seoul, Suwon

2022-12-29

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Seoul

2022-12-21

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Daegu, Jeonju, Seoul

2022-12-13

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Busan, Daegu, Goyang-si, Seongnam-si, Seoul

2022-11-28

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Cheongju-si, Seoul, Suwon

2022-09-15

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Seoul

2022-09-06

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Goyang, Seoul

2022-08-11

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon

2022-08-03

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594Advanced Solid Malignancies

DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide

AstraZeneca

Phase 1/2

695

Seoul

2022-06-24

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Busan, Daegu, Seoul

2022-05-16

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Busan, Gwangju, Seoul

2022-04-19

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Busan, Chungcheongbuk-do, Seongnam-si, Seoul, Suwon

2022-04-14

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Lenvatinib·Durvalumab

AstraZeneca

Phase 3

760

Busan, Daegu, Goyang-si, Junggu, Seoul

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Bukgu, Busan, Goyang-si, Seoul

2022-03-25

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Daegu, Jinju, Seoul, Suwon

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon

2022-02-18

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Changwon-si, Cheongju-si, Seongnam-si, Seoul, Suwon

2022-02-07

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Seongnam-si, Seoul

2021-12-10

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Daejeon, Goyang-si, Incheon, Seoul

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Cheongju-si, Goyang-si, Gyeonggi-do, Seoul

2021-10-28

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Goyang-si, Seoul

2021-10-25

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Goyang-si, Seoul

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Seoul

2021-10-18

Active, closed

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523Non-Small-Cell Lung Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

212

Seoul

2021-09-14

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Busan, Goyang-si, Incheon, Seongnam-si, Seoul

2021-08-05

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Cheonan-si, Daegu, Goyang-si, Seongnam-si, Seoul

2021-06-30

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Goyang-si, Seoul

2021-05-10

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Cheonan-si, Daegu, Goyang-si, Seoul

2021-04-26

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Cheongju-si, Goyang-si, Jinju, Seoul

2021-03-09

Active, closed

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma

DrugSurovatamig

AstraZeneca

Phase 1

226

Seoul

2021-03-02

Active, closed

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689Small-Cell Lung Cancer

DrugsEtoposide·Durvalumab·Cisplatin·Carboplatin

AstraZeneca

Phase 2

Cheongju-si, Jinju, Seoul

2021-02-23

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Busan, Daegu, Goyang-si, Seoul

2021-01-28

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Seoul

2020-12-30

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

Busan, Seoul

2020-12-28

Active, closed

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773Metastatic Breast Cancer

DrugsCapivasertib·Anastrozole·Trastuzumab deruxtecan·Fulvestrant

AstraZeneca

Phase 1

138

Seoul

2020-12-17

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Daegu, Hwasun-gun, Incheon, Seoul, Yangsan

2020-12-16

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Hwasun-gun, Seongnam-si, Seoul

2020-11-17

Active, closed

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer

DrugsSaruparib·Camizestrant·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

702

Seoul

2020-11-12

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Daegu, Seoul, Suwon

2020-10-19

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Busan, Cheongju-si, Goyang-si, Seongnam-si, Seoul

2020-10-02

Active, closed

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

477

Seoul

2020-08-18

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Seoul

2020-08-04

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Daegu, Goyang-si, Incheon, Seongnam-si, Seoul

2020-07-24

Active, closed

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304Hypereosinophilic Syndrome

DrugBenralizumab

AstraZeneca

Phase 3

134

Seoul

2020-07-20

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Daegu, Goyang-si, Seongnam-si, Seoul

2020-07-13

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Seongnam-si, Seoul

2020-06-03

Active, closed

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200Endometrial Neoplasms

DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

805

Goyang-si, Seoul, Suwon, Yangsan

2020-05-05

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon

2020-04-16

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Cheongju-si, Goyang-si, Seoul

2019-07-02

Active, closed

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772Non-Small Cell Lung Cancer

DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib

AstraZeneca

Phase 2

247

Seongnam-si, Seoul

2019-06-25

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul

2019-06-25

Active, closed

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235Biliary Tract Neoplasms

DrugDurvalumab

AstraZeneca

Phase 3

810

Seongnam-si, Seoul

2019-04-16

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Cheongju-si, Goyang-si, Gyeonggi-do, Seoul

2019-03-06

Active, closed

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229Carcinoma

DrugsSavolitinib·Osimertinib

AstraZeneca

Phase 2

367

Goyang-si, Seongnam-si, Seoul, Suwon

2019-01-09

Active, closed

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643Advanced Ovarian Cancer

DrugsOlaparib·Durvalumab·Paclitaxel·Bevacizumab

AstraZeneca

Phase 3

1,407

Goyang-si, Seongnam-si, Seoul, Suwon

2019-01-04

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsDanvatirsen·Oleclumab·Volrustomig·Rilvegostomig

AstraZeneca

Phase 1

175

Cheongju-si, Seoul

2018-12-27

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102Triple Negative Breast Neoplasms

DrugsOleclumab·Capivasertib·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

243

Seoul

2018-12-21

Active, closed

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486Non-small Cell Lung Cancer NSCLC

DrugsOlaparib·Durvalumab·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 2

401

Dongjakgu, Goyang-si, Seodaemun-gu, Seoul, Suweonsi Paldalgu

2018-12-21

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Busan, Cheongju-si, Seongnam-si, Seoul, Suwon

2018-12-06

Active, closed

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957Hepatocellular Carcinoma

DrugsAvastin·Durvalumab·Bevacizumab

AstraZeneca

Phase 3

724

Busan, Daegu, Goyang-si, Seoul

2018-11-30

Active, closed

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

NCT03706690Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

407

Daegu, Gwangju, Seoul

2018-11-27

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul

2018-11-16

Active, closed

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Metastatic Castration-resistant Prostate Cancer

DrugsZytiga·Abiraterone acetate·Olaparib

AstraZeneca

Phase 3

895

Daegu, Goyang-si, Seoul

2018-10-31

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

730

Changwon-si, Cheongju-si, Daegu, Goyang-si, Jinju, Seongnam-si, Seoul, Suwon

2018-09-27

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Goyang-si, Incheon, Seoul, Suwon

2018-09-27

Active, closed

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154Non Small Cell Lung Cancer (Stage III)

DrugOsimertinib

AstraZeneca

Phase 3

216

Cheongju-si, Incheon, Seongnam-si, Seoul

2018-07-19

Active, closed

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846Urinary Bladder Neoplasms

DrugsOlaparib·Durvalumab

AstraZeneca

Phase 2

154

Incheon, Seoul

2018-03-16

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul

2018-03-07

Active, closed

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617Non-Small Cell Lung Cancer

DrugsDanvatirsen·Vistusertib·Cediranib Maleate·Ceralasertib

AstraZeneca

Phase 2

528

Seoul

2017-12-18

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Ilsan, Seongnam-si, Busan, Daegu, Seoul

2017-10-11

Active, closed

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms

DrugsSavolitinib·Sunitinib

AstraZeneca

Phase 3

Daejeon, Goyang-si, Hwasun-gun, Incheon, Seoul

2017-07-25

Active, closed

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616Non Small Cell Lung Cancer NSCLC

DrugsTremelimumab·Abraxane·Durvalumab·Pemetrexed

AstraZeneca

Phase 3

1,186

Busan, Chungcheongbuk-do, Daegu, Incheon, Seongnam-si, Seoul, Ulsan

2017-06-01

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

Changwon, Cheongju-si, Daegu, Incheon, Jinju, Seongnam-si, Seoul

2017-03-27

Active, closed

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962Non Small Cell Lung Carcinoma NSCLC

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

669

Changwon-si, Cheongju-si, Daegu, Incheon, Jinju, Seoul, Suwon

2017-01-02

Active, closed

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004Ovarian, Breast, SCLC, Gastric Cancers

DrugsAvastin·Olaparib·Durvalumab·Bevacizumab

AstraZeneca

Phase 1/2

264

Goyang-si, Seongnam-si, Seoul

2016-03-17

Active, closed

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293Non Small Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

953

Daegu, Hwasun-gun, Seoul

2015-11-03

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Incheon, Seongnam-si, Seoul

2015-11-02

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Cheongju-si, Seoul, Suwon

2015-10-21

Active, closed

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

DrugsSaruparib·Olaparib·Durvalumab·Carboplatin

AstraZeneca

Phase 1

358

Goyang-si, Seongnam-si, Seoul

2014-10-31

Active, closed

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466Advanced Non Small Cell Lung Cancer

DrugsSavolitinib·Selumetinib·Osimertinib·Durvalumab

AstraZeneca

Phase 1

344

Cheongju-si, Goyang-si, Seongnam-si, Seoul

2014-08-05

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

Daegu, Goyang-si, Incheon, Seongnam-si, Seoul

2014-04-22

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

DrugOlaparib

AstraZeneca

Phase 3

327

Seoul

2013-09-03

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

DrugOlaparib

AstraZeneca

Phase 3

450

Goyang-si, Seoul

2013-08-26

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 195 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

91 of the 195 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 100 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 195 studies
Phase	Studies	Recruiting	Share
Phase 3	120	48	61.5%
Phase 2	30	13	15.4%
Phase 1/2	26	20	13.3%
Phase 1	11	4	5.6%
Observational	8	6	4.1%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsor	Studies	Recruiting
AstraZeneca	195	91

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.